Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02224339 |
| Other study ID # |
14-000555 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
September 2014 |
| Est. completion date |
January 2019 |
Study information
| Verified date |
March 2019 |
| Source |
Mayo Clinic |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Hypothesis: Identification of vulnerable atherosclerotic plaques (with or without
neovascularization) using carotid CEUS is an independent predictor of MACE (over clinical
risk factors, stress echo wall motion results, and carotid ultrasound two-dimensional speckle
tracking strain indices).
Primary Aims:
1. Evaluate the diagnostic role of carotid CEUS and two-dimensional speckle tracking strain
imaging for detection of carotid plaque:
- To determine the feasibility and safety of Carotid CEUS and Two-dimensional speckle
tracking strain imaging SE .
- To determine if carotid CEUS and two-dimensional speckle tracking strain imaging
findings are associated with coronary angiographic results in those patients
undergoing clinically indicated cardiac catheterization.
- To determine the diagnostic accuracy of CEUS in identifying a vulnerable
atherosclerotic plaque and neovascularization compared to carotid MRI, in a subset
of patients.
2. Evaluate the prognostic role of carotid CEUS and two-dimensional speckle tracking strain
imaging for prediction of MACE:
- To determine if plaque identification (with or without neovascularization) on
Carotid CEUS SE can improve the overall prediction of MACE over stress echo results
alone
- To determine if Carotid ultrasound two-dimensional speckle tracking strain indices
can improve the overall prediction of MACE over stress echo results alone.
- To determine if the detection of plaque neovascularization by Carotid CEUS is an
independent predictor of MACE (over clinical risk factors, stress echo wall motion
results, and carotid ultrasound two-dimensional speckle tracking strain indices).
Description:
This is a prospective cohort study. - Participating Site(s) (principal investigators in
parentheses) that will be enrolling patients will be: Mayo Clinic Rochester site (PI: Sharon
Mulvagh, MD). Only subjects who provide their informed consent will be included. Patients
will be prospectively identified at the time they present to the echocardiography laboratory
and scheduled to undergo exercise or dobutamine stress testing for the reason of known or
suspected CAD. The patients will undergo a carotid artery ultrasound with and without
contrast, carotid artery strain imaging and stress echo with contrast in same setting as
detailed in study flow chart. MRI will be performed in a subset of a randomly selected
patient (50 pts) to ascertain the diagnostic accuracy of CEUS in plaque identification. All
patients will be followed up by reviewing electronic medical records (EMR) and/ or phone
contact using standardized approved questionnaire survey at 6 and 12 and 24 months after
ultrasound studies have been completed. The outcome is major adverse cardiac events (MACE)
including cardiac death, acute coronary syndrome (ACS), unstable angina pectoris, nonfatal
acute myocardial infarction, and stroke. Study eligibility criteria: age ≥ 18 years,
suspected or known to have CAD and referred to stress echo lab. Study Exclusion criteria:
Previous carotid surgery or angioplasty; Stroke, cardiogenic shock, pulmonary hypertension,
heart failure; other serious disease; Prior contraindication to contrast agent.
1.Study Procedures: Carotid artery ultrasound (2D and CEUS) will be performed during the
resting phase of stress echocardiography in each patient. Transthoracic SE [exercise or
dobutamine] will be performed by an experienced sonographer/echocardiographer according to
the American Society of Echocardiography recommendations.
2.Imaging protocol: Commercially available ultrasound system (Vivid, GE Medical Systems,
Milwaukee, WI, USA) equipped with phased-array transducers, and contrast imaging technology
will be utilized. OptisonTM (GE Healthcare Inc., Princeton, NJ)] will be used for CEUS and
left ventricular opacification (LVO) for wall motion score index (WMSI). 2D carotid US,
carotid strain, CEUS and Contrast SE will be performed in succession. The contrast agent will
be administered per package insert guideline for dosing. The commercially available real time
coherent pulse imaging (CPI) low Mechanical index contrast imaging schemes will be utilized.
1. Standard carotid ultrasound: Longitudinal and short axis images of each carotid artery
will be acquired and digitally stored for off line strain analysis. The short axis
images will be acquired 1.5 cm from the bifurcation.
2. Carotid CEUS: The contrast agent will be injected via a peripheral vein as a bolus per
package insert. The appearance of the contrast effect will be observed inside the lumen
of the carotid artery within 15-30 seconds after the injection. A real-time
contrast-enhanced carotid cine-loop (longitudinal and short axis) including images
obtained at least 3 seconds before and 5 minutes after the appearance of the contrast
effect in the lumen of the carotid artery, will be acquired and digitally stored for off
line analysis. The entire imaging session will be digitized and recorded on videotape
and digitally for subsequent offline analysis. All echocardiographic measures will be
made in a blinded fashion by a single observer.
3. MRI: 50 pts will be randomly selected to undergo Carotid MRI within the same episode of
care (+/- 4 weeks) to determine the diagnostic accuracy of CEUS in identifying a
vulnerable atherosclerotic plaque and neovascularization.The carotid imaging protocol
will involve a standard 2D carotid ultrasound imaging and CEUS imaging as follows.
3.Trial Variables:
Patient identifiers for this study will be stored on a single electronic spreadsheet that is
password protected and stored on the Mayo EED network. Unique identifiers will be converted
to a study identifier (ID). Only the primary study investigator will have access to the
spreadsheet. The study ID numbers will be maintained on the statistical software spreadsheet
and stored on a password protected departmental server on the Mayo EED. Data will be entered
in statistical software for computer analysis, archiving and storage. All study data will be
reviewed by the study investigators to ensure complete data collection. All study data will
be used only for research purposes, and will not impact medical care and/or decision-making.
There will not be publication of any variable potentially involved with patient
identification. Patient confidentiality will be strictly protected. Trial variables will
include:
1. Demographics and Labs:
Age, gender, BMI Cardiovascular risk factor Symptom/disease duration (years) Medications
Laboratory Investigations including Lipids (µmol/L) hs-CRP (mg/L) (if available
clinically) BS or HbA1C (if diabetes mellitus)
2. Carotid imaging: Intima medial thickness (IMT) and plaque identification (2-D baseline)
Longitudinal and short axis images of each carotid artery will be obtained to measure
CIMT, defined as the distance from the leading edge of the lumen-intima interface to the
leading edge of the media-adventitia interface. The measurement region will be
approximately 1.5 cm distal to the carotid bulb. Atherosclerotic plaques will be defined
as lesions with a focal IMT ≥1.1 mm or more that protrude from the vessel wall into the
lumen.
The plaque echogenicity will be assessed by Gray-Weale's (type I-V): type I: dominantly
echolucent plaque, with a thin echogenic cap; type II: predominantly echolucent lesions
with <50% echogenic areas; type III: predominantly echogenic lesions with <50%
echolucent areas; type IV: uniformly echogenic lesions; type V: plaques with heavy
calcification and acoustic shadows. Types I and II are as fatty plaques, types III and
IV are as mixed plaques and type V are as calcified plaques.
3. Strain imaging Measurements are performed offline on the workstation using Echo PAC
software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the
carotid arterial wall will be manually traced from a still frame image. The
circumferential and radial strain curves will be automatically obtained. Measurements of
the peak radial and circumferential strain, strain rate will be obtained. If carotid
plaque identified: An ROI (regional of interest) will be placed at the plaque 3
different regions: 2 shoulder regions and the fibrous cap top, the measurement results
of the peak longitudinal, radial and circumferential strain, strain rate will be
acquired by the software.
4. Carotid CEUS The enhancement of each plaque will be categorized by visual
interpretation, G0: no visible microbubbles within the plaque; G1: moderate microbubbles
confined to the shoulder and/or adventitial side of the plaque; or G2: extensive
microbubbles throughout the plaque, with clear visible appearance of bubble moving into
the plaque core. The quantitative of the enhancement of plaque will be analyzed by using
time-intensity curve. Quantitative parameters will be obtained: BI (baseline intensity),
PI (peak intensity) and EI (enhanced intensity: peak intensity/ baseline intensity).
Stress Echo:
5. Stress echo data analysis will be per the Mayo Clinic Echocardiography Laboratory
(Rochester MN) stress protocol and generated clinical report. The analysis utilizes the
American Heart Association/American Society of Echocardiography 17-segment model. Wall
motion is evaluated using previously established criteria (29) and rest and stress wall
motion score indexes (WMSIs) are calculated. Wall motion is assessed by scoring as
follows: 1=normal, 2=hypokinetic, 3=akinetic and 4=dyskinetic.
6. Magnetic Resonance Imaging (MRI) validation subset: 50 pts will be randomly selected to
undergo Carotid MRI (per standard imaging protocol) within the same episode of care (+/-
4 weeks). The carotid MRI studies will be sent to Michigan State University via a secure
VPN or similarly secure transfer. The reader will be blinded to the clinical data. The
study will utilize a General Electric 3T scanner with dedicated carotid coils.
Multi-contrast carotid plaque sequences including 3D time-of-flight MR angiography
(TOF), a 3D black-blood sequence optimized to detect intraplaque hemorrhage (MPRAGE) and
pre-contrast black-blood T1 weighting (T1W). During bolus administration of a single
dose of gadolinium based contrast agent, a dynamic contrast enhanced MR study (DCE-MRI)
will be obtained as well post-contrast black-blood T1 weighted sequence (CE-T1W).
7. Outcomes:
All patients will be followed up by reviewing electronic medical records (EMR) and/ or phone
contact using standardized approved questionnaire survey at 6 and 12 and 24 months after
ultrasound studies have been completed. The outcome is defined as presence or absence of
major adverse cardiac events (MACE) including cardiac death, acute coronary syndrome (ACS),
unstable angina pectoris, nonfatal acute myocardial infarction, and stroke.
4.Power and sample size calculation: We use several published papers as reference for sample
size estimation. Odds ratio MACE rate Patient population Feinstein 2.5(1.1-6.1) 25%(37/147)
147 Kugiyama 2.52(1.42-4.38) 28%(84/304) 304
Patients recruited in these references were at high risk or had known CAD. Since our patients
will include a spectrum of CV risk, we have estimated the hazards ratio to be 1.5-3.0, and
MACE rate at 5-20%. Our statistical resource suggested a sample of 180 patients to provide
80% test power (2-tailed test with α of 0.05) to detect an association of plaque
neovascularization with MACE (HR 2.8, MACE RATE 20%). Anticipating ~20% F/U failure or
withdrawals, we inflated to a total of 216 patients. The primary endpoint is the cumulative
incidence of cardiac death within 24 months followup. The secondary endpoint is composite
MACE. For the followup data, the missing data will be reported as missing, unavailable.
5.Statistical analysis Plan Baseline and demographic descriptive analysis including age,
gender, parity, weight, height, Body mass index (BMI), body surface area (BSA),
cardiovascular risk factors, will be presented. Counts and percentages will be presented for
categorical variables, while means ±standard deviations and 95% confidence intervals will
describe continuous variables for which normality assumptions are met. If the distribution of
a continuous parameter is skewed, transformations will be considered, or medians and
interquartile ranges (IQR) will be presented. For all analysis we will use a two sided P
value less than 0.05 to be significant and all tests will be performed using SAS 9.1 (SAS
Institute, Cary, NC). Echo feasibility analysis will be evaluated by reporting the percentage
of the analyzable plaques and myocardial segments (for CEUS, WMSI and strain). Safety on the
use of Optison contrast agent will be also evaluated and reported as (%) of adverse events
(categorized as minor or serious adverse events). Measures of data will be reported as mean ±
SD for continuous variables (including quantitative parameters of contrast enhanced in the
plaque and quantitative parameters of strain). The intraplaque neovascularization will be
counted and displayed as percentage. After the SE and CEUS examination, patients will be
grouped as the result of SE and CEUS: group I: with plaque neovascularization and without
abnormal wall motion; group II: without plaque neovascularization and with abnormal wall
motion; group III: without plaque neovascularization and with abnormal wall motion; group IV:
with plaque neovascularization and with abnormal wall motion. Continuous variables will be
compared between 2 groups using unpaired t-tests. For comparison of continuous variables in
≥3 groups, one-way analysis of variance (ANOVA) followed by a Scheffé test was performed.
Frequencies will be compared using Chi square analysis. The correlation between 2 continuous
variables will be determined using a linear regression analysis. The relationship between
cardiovascular risk factors and the grade of plaque neovascularization will be examined using
multiple logistic regression analysis. Cox proportion hazard model is used to estimate the
hazard ratio of prediction of CV. The Kaplan-Meier method is used to calculate coronary
event-free survival in patients with and without intraplaque contrast material enhancement.
Intra- and interobserver agreement for assigning grade to plaque neovascularization will be
evaluated using the Cohen κ test. Observer reproducibility of parameters will be assessed by
using Bland-Altman in 20 randomly assigned patients, by two independent observers blinded to
clinical data. Intraobserver variability will be assessed in the same patients by the same
investigator in 2 occasions at least 1 month apart. All statistical analyses will be
performed using JMP version 9 (SPSS Inc, Chicago, IL).
